TY - JOUR
T1 - VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma
AU - Morasca, L.
AU - Marsoni, S.
AU - Pisoni, M. Brambilla
AU - Piazza, E.
AU - Vago, G.
AU - Casali, W.
AU - Cogo, R.
AU - Bainchi, C.
AU - Scapaticci, R.
PY - 1982
Y1 - 1982
N2 - Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.
AB - Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.
UR - http://www.scopus.com/inward/record.url?scp=0020045458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020045458&partnerID=8YFLogxK
U2 - 10.1007/BF00254551
DO - 10.1007/BF00254551
M3 - Article
C2 - 7083461
AN - SCOPUS:0020045458
SN - 0344-5704
VL - 7
SP - 209
EP - 210
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 2-3
ER -